The ophthalmology-focused precision medicine developer has licensed research from several universities, including Edinburgh.
Gemini Therapeutics, a US-based ophthalmology-focused precision medicine developer with ties to several universities, has raised a $42.5m series A round co-led by VC firms Atlas Venture, Lightstone Ventures and Orbimed.
Gemini is working on gene-based therapeutics for patients suffering from dry age-related macular degeneration (AMD), a condition which damages part of the retina, causing blurred vision and blindness.
The company was co-founded in 2015 by Paul Barlow, professor of structural biology at Edinburgh’s School of Chemistry, and Andy Herbert, structural…